Skip to main content

Table 3 Total and drug-related serious adverse events, hospitalizations, and discontinuations

From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

  Total AEs Drug-related AEs
Subgroup SAEs Hosp D/C SAEs Hosp D/C
Anemia, n (%)
 PTCL 2 (2) 2 (2) 0 2 (2) 2 (2) 0
 CTCL 1 (1) 1 (1) 0 1 (1) 1 (1) 0
Neutropenia, n (%)       
 PTCL 7 (5) 7 (5) 2 (2) 5 (4) 5 (4) 2 (2)
 CTCL 2 (2) 0 1 (1) 2 (2) 0 1 (1)
Thrombocytopenia, n (%)
 PTCL 2 (2) 1 (1) 3 (2) 1 (1) 1 (1) 3 (2)
 CTCL 0 0 1 (1) 0 0 1 (1)
Nausea and vomiting, n (%)
 PTCL 6 (5) 6 (5) 0 4 (3) 4 (3) 0
 CTCL 0 0 0 0 0 0
Asthenic conditions, n (%)
 PTCL 2 (2) 2 (2) 2 (2) 0 0 1 (1)
 CTCL 2 (2) 1 (1) 4 (4) 1 (1) 1 (1) 4 (4)
Infections, n (%)
 PTCL 25 (19) 21 (16) 6 (5) 6 (5) 3 (2) 2 (2)
 CTCL 8 (8) 8 (8) 5 (5) 5 (5) 5 (5) 3 (3)
  1. AE, adverse event; CTCL, cutaneous T-cell lymphoma; D/C, discontinuations; Hosp, hospitalizations; PTCL, peripheral T-cell lymphoma; SAEs, serious adverse events.